SHANGHAI, Oct. 14, 2013 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology and medical device R&D outsourcing company with operations in China and the United States, today announced that it will release financial results for the third quarter of 2013 after the New York Stock Exchange closes on Tuesday, November 12, 2013 (which will be Wednesday morning, November 13, 2013 Shanghai time). The earnings release will be available on the investor relations section of the Company’s website at http://www.wuxiapptec.com/.
Following the earnings announcement, WuXi PharmaTech senior management will host a conference call at 8:00 am (U.S. Eastern) / 5:00 am (U.S. Pacific) / 9:00 pm (Beijing/Shanghai/Hong Kong) on Wednesday, November 13, 2013, to discuss the third-quarter 2013 financial results and recent business activities. The conference call may be accessed by calling:
China | 4001 200 539 |
Hong Kong | 800 905 927 |
Singapore | 800 616 3222 |
United Kingdom | 0800 015 9725 |
United States | 1855 298 3404 |
United StatesNew York (toll) | +1 631 5142 526 |
Other countries (toll) | +65 6823 2299 |
Conference ID | 5522969 |
A telephone replay will be available two hours after the call’s completion at:
China | 4001 842 240 |
Hong Kong | 800 966 697 |
Singapore | 800 616 2127 |
United Kingdom | 0800 169 7301 |
United States | 1866 846 0868 |
Conference ID | 5522969 |
A live webcast of the conference call and replay will be available in the investor relations section of WuXi PharmaTech’s website at http://www.wuxiapptec.com/.
About WuXi PharmaTech
WuXi PharmaTech is a leading pharmaceutical, biotechnology and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceutical, biotechnology and medical device companies with a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech’s services are designed to help its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. The operating subsidiaries of WuXi PharmaTech are known as WuXi AppTec.
For more information, please contact:
Ronald Aldridge
Director of Investor Relations
WuXi PharmaTech (Cayman) Inc.
Tel: +1-201-585-2048
Email: Ron_Aldridge@wuxiapptec.com
Web: http://www.wuxiapptec.com
SOURCE WuXi PharmaTech (Cayman) Inc.
Help employers find you! Check out all the jobs and post your resume.
